公开(公告)号：US20140343093A1

公开(公告)日：2014-11-20

申请号：US14366857

申请日：2012-12-12

Applicant: Novartis AG

Inventor： Daniel Ford ,  John Robert Porter ,  Michael Scott Visser ,  Naeem Yusuff

IPC: C07D401/10

CPC classification number: C07D401/10

Abstract: The present invention relates to compounds of formula I: in which R1, R2, R3 and R4 are as defined in the Summary of the Invention. Compounds of formula I are capable of disrupting the BCL-2 interations with proteins containing a BH3 domain. Disrupting this interaction can restore the anti-apoptotic function of BCL-2 in cancer cells and tumor tissue expressing BCL-2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancerous diseases.